Cidara Therapeutics (CDTX) News Today

StockNews.com upgraded Cidara Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 100,700 shares, a decrease of 11.7% from the July 15th total of 114,000 shares. Based on an average daily trading volume, of 38,500 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.5% of the shares of the company are short sold.

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Cidara Therapeutics in a research note issued on Wednesday, August 14th. HC Wainwright analyst E. Arce forecasts that the biotechnology compan

Cantor Fitzgerald reiterated an "overweight" rating on shares of Cidara Therapeutics in a report on Wednesday.

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below 50 Day Moving Average of $12.22

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have received an average rating of "Buy" from the four ratings firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a buy rating and one has given a stro

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above 50 Day Moving Average of $12.27

Cidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above 50-Day Moving Average of $12.23

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 113,600 shares, an increase of 5.8% from the May 31st total of 107,400 shares. Currently, 2.6% of the shares of the company are sold short. Based on an average trading volume of 74,900 shares, the days-to-cover ratio is presently 1.5 days.

Cantor Fitzgerald restated an "overweight" rating on shares of Cidara Therapeutics in a research note on Thursday.

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 107,400 shares, an increase of 53.2% from the May 15th total of 70,100 shares. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily volume of 70,600 shares, the days-to-cover ratio is presently 1.5 days.

Shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) have earned an average recommendation of "Buy" from the four analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a buy recommendation and one has given a strong buy r

Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 70,100 shares, a decline of 16.2% from the April 30th total of 83,700 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 67,000 shares, the short-interest ratio is currently 1.0 days.

Cidara Therapeutics (NASDAQ:CDTX) Stock Passes Below Fifty Day Moving Average of $14.59

Needham & Company LLC reiterated a "buy" rating and set a $25.00 target price on shares of Cidara Therapeutics in a report on Thursday.

Cidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst Upgrade

WBB Securities reissued a "strong-buy" rating and set a $40.00 price target on shares of Cidara Therapeutics in a report on Thursday.

Needham & Company LLC increased their target price on Cidara Therapeutics from $3.00 to $25.00 and gave the company a "buy" rating in a report on Thursday.

Cidara Therapeutics (NASDAQ:CDTX) Shares Up 7.1%